The Efficacy and Safety of Sunitinib in Patients With Advanced Well-differentiated Pancreatic Neuroendocrine Tumors
conference contribution
posted on 2017-03-01, 00:00authored byEric Raymond, Matthew Kulke, Shukui Qin, Michael Schenker, Antonio Cubillo, Wenhui Lou, Jiri Tomasek, Espen Thiis-Evensen, Jianming Xu, Karoly Racz, Adina Croitoru, Mustafa Khasraw, Eva Sedlackova, Ivan Borbath, Paul Ruff, Paul Oberstein, Tetsuhide Ito, Kathrine Fernandez, Brad Rosbrook, Nicola Fazio
The Efficacy and Safety of Sunitinib in Patients With Advanced Well-differentiated Pancreatic Neuroendocrine Tumors